GH secretagogue
GHRP-2 Dosage, Protocol & Research Guide
- MW 818 g/mol
- CAS 158861-67-7
Dose overview
Every range below is taken from the cited source and carries its evidence grade.
Human data and community reports
| Source | Population | Dose | Frequency | Route | Duration | Evidence |
|---|---|---|---|---|---|---|
| Endocr J 2010 (doi 10.1507/endocrj.k09e-273)[1] | humanhealthy men (n = 10) | 100 mcg[1]intravenous | single intravenous bolus | intravenous | — | Human clinical trialStudy details from the source: Endocr J 2010 (doi 10.1507/endocrj.k09e-273): intravenous bolus of 100 mcg GHRP-2 in 10 healthy men, fasting and non-fasting; GH, ACTH and prolactin peaked at 15-30 min; vasopressin, blood pressure, hematocrit and plasma osmolality did not change |
Evidence grades: A approved label, B human trial, C observational, D animal study, E community-reported.
Reconstitution calculator
Calculator example, not a recommended amount
- Concentration
- 2.5 mg/mL
- Volume to draw
- 0.1 mL
- Units on a U-100 syringe
- 10 units
Properties
- CAS
- 158861-67-7
- Molecular weight
- 818 g/mol
- Formula
- Not yet recorded
- Sequence
- Not yet recorded
- Aliases
- Pralmorelin, KP-102
- Vial sizes (mg)
- 5
Storage notes
- Lyophilized
- Not yet recorded from a cited source
- Reconstituted stability (days)
- Not yet recorded from a cited source
Side effects, contraindications and regulatory status
Reported side effects
- In seven lean healthy men, a 270-minute subcutaneous GHRP-2 infusion (1 mcg/kg/h) increased food intake at a buffet meal by about 36% compared with saline.[2] Human trial
- After a 100 mcg intravenous bolus in 10 healthy men, blood pressure, hematocrit and plasma osmolality did not change; ACTH and prolactin rose along with GH.[1] Human trial
Report any adverse reaction to a qualified healthcare professional.
What the research says
Summaries of the cited studies, each with its evidence grade.
Endocr J 2010 (doi 10.1507/endocrj.k09e-273)[1]
Endocr J 2010 (doi 10.1507/endocrj.k09e-273): intravenous bolus of 100 mcg GHRP-2 in 10 healthy men, fasting and non-fasting; GH, ACTH and prolactin peaked at 15-30 min; vasopressin, blood pressure, hematocrit and plasma osmolality did not change
J Clin Endocrinol Metab 2005 (doi 10.1210/jc.2004-1243)[2]
J Clin Endocrinol Metab 2005 (doi 10.1210/jc.2004-1243): subcutaneous infusion of GHRP-2 at 1 mcg/kg/h for 270 min in seven lean healthy men; food intake at a buffet meal was 35.9% higher than with saline and GH rose
J Pediatr Endocrinol Metab 1996 (doi 10.1515/jpem.1996.9.s3.261)[3]
J Pediatr Endocrinol Metab 1996 (doi 10.1515/jpem.1996.9.s3.261): normal younger and older men and women received GHRP-2, GHRH or both for 7-30 days; chronic GHRP-2 or GHRH turned an additive GH response into a synergistic one, and desensitisation depended on dose and frequency
Frequently asked questions
What dose figures are published for GHRP-2?
Cited figures on this page: 100 mcg single intravenous bolus, intravenous [1] (Human clinical trial, evidence grade B). These are summaries of published sources, not medical advice. Each figure links to its source in the references.
Compound facts
What is the molecular weight of GHRP-2?
What is the CAS number of GHRP-2?
How is GHRP-2 stored in the laboratory?
References
Numbered sources used on this page. Markers in the text link here.
- Endocr J 2010 (doi 10.1507/endocrj.k09e-273) pubmed.ncbi.nlm.nih.gov Human trial
- J Clin Endocrinol Metab 2005 (doi 10.1210/jc.2004-1243) pubmed.ncbi.nlm.nih.gov Human trial
- J Pediatr Endocrinol Metab 1996 (doi 10.1515/jpem.1996.9.s3.261) pubmed.ncbi.nlm.nih.gov Human trial